Professor Timothy Tree Academics Supervisors Professor of Immune Regulation and Immunotherapy Co-Director of the Programme of Infection & Immunity. Research subject areas Immunology Contact details timothy.tree@kcl.ac.uk (0) 20 7848 9611
A set of circulating microRNAs belonging to the 14q32 chromosome locus identifies two subgroups of individuals with recent-onset type 1 diabetes Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer IL-2-based approaches to Treg enhancement Senescent-like Blood Lymphocytes and Disease Progression in Amyotrophic Lateral Sclerosis Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency Monitoring islet specific immune responses in type 1 diabetes clinical immunotherapy trials Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes Regulatory T cells in the peripheral blood of women with gestational diabetes: a systematic review and meta-analysis Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote transplantation tolerance in humans Concordance of B- and T-cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19 INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes The Expression of Active CD11b Monocytes in Blood and Disease Progression in Amyotrophic Lateral Sclerosis Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study Study protocol: Minimum effective low dose: Anti-human thymocyte globulin (MELD-ATG): Phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer Phase II multicentre, double-blind, randomised trial of ustekinumab in adolescents with new-onset type 1 diabetes (USTEK1D): Trial protocol Augmented Expansion of Treg Cells From Healthy and Autoimmune Subjects via Adult Progenitor Cell Co-Culture Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2 The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate Mapping T Cell Responses to Native and Neo-Islet Antigen Epitopes in at Risk and Type 1 Diabetes Subjects Historical and new insights into pathogenesis of type 1 diabetes (2) Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease Identifying the ‘Achilles heel’ of type 1 diabetes Type 1 diabetes can present before the age of 6 months and is characterised by autoimmunity and rapid loss of beta cells Autoreactive T cell profiles are altered following allogeneic islet transplantation with alemtuzumab induction and re-emerging phenotype is associated with graft function Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial Tracking immunodynamics by identification of S-G2/M-phase T cells in human peripheral blood GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression Historical and new insights into pathogenesis of type 1 diabetes Phenotypic analysis of human lymph nodes in subjects with new-onset type 1 diabetes and healthy individuals by flow cytometry Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) Standardizing T-Cell biomarkers in type 1 diabetes: Challenges and recent advances Persistent C-peptide is associated with reduced hypoglycaemia but not HbA1c in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice? Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis Immunological biomarkers for the development and progression of type 1 diabetes Multipotent Adult Progenitor Cells Suppress T Cell Activation in Models of Homeostatic Proliferation in a Prostaglandin E2-Dependent Manner 315 - Multipotent Adult Progenitor Cells suppress homeostatic driven activation of T cells in vivo: ISCT 2018 Annual Meeting Metabolic and immune effects of immunotherapy with proinsulin peptide in new-onset type 1 diabetes Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it? View all publications
31 July 2024 Psoriasis drug shows promise for treating childhood diabetes A drug commonly used to treat psoriasis, Ustekinumab, has been found to be effective in helping to…